Cell‐based therapies using human multipotent stromal cells (hMSC) to dampen autoimmunity while inducing islet regeneration represents a promising approach to treat diabetes. However, poor survival and retention of transplanted hMSC in the damaged pancreas complicates clinical translation. The research demonstrated that hMSC secrete an array of islet‐regenerative proteins and intrapancreatic delivery of hMSC‐conditioned media (CM) could stimulate islet regeneration without the need for cell transfer. Wnt‐pathway stimulated hMSC CM‐injection set in motion a cascade of events consistent with the emergence of functional islets. Discovery of hMSC‐secreted, islet‐regenerative effectors may lead to the development of cell‐free therapies to combat diabetes.
Although it has been reported that soluble cytokines based on mesenchymal stem cells (MSCs) therapy that could attenuate radiation‐induced lung injury (RILI), the mechanism of MSC‐based secretome therapy for RILI is still not fully understood. This review summarized the recent progress regarding the potential mechanisms of MSCs therapy for RILI, with an emphasis on MSC‐secreted cytokines and miRNAs as a safe and, effective cell‐free therapy, which may be helpful to accelerate the strategy from bench to bedside.
Research identifies hBM-MSC derived factors that promote islet regenerative and may permit the development of cell‐free therapies for diabetic patients